MindMaze Therapeutics secures up to CHF 4 million financing
MindMaze Therapeutics announced agreements for up to CHF 4 million from long-term strategic investors, with CHF 3 million scheduled for November and December 2026 and an option for an additional CHF 1 million until February 28, 2027. The proceeds will support the wider commercial deployment of its neurotherapeutics platform and the launch of MindMotion Lite for home deployment.
Primary source
Company press release (PR Newswire), November 17, 2026
MindMaze Therapeutics Announces CHF 4 Million Financing
Read the source: MindMaze Therapeutics Announces CHF 4 Million Financing prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation